Ehave, Inc. Completes Acquisition of Psychedelitech, Inc. (“PsyTech”)

MIAMI, FL–May 06, 2020–Ehave, Inc. has finalized its acquisition of Psychedelitech (“PsyTech”) in its Mycotopia subsidiary, and now owns PsyTech’s two divisions, PsyTech Connect and PsyTech Discovery. PsyTech Connect is the psychedelic community platform for live and virtual conferences and an online portal for psychedelics content.  PsyTech Discovery will develop ventures in psychedelic therapeutics and education.

Through this transaction, Ehave, Inc. will build on its plan to nurture the development of therapies using psychedelics. Through PsyTech’s ecosystem, Ehave, Inc. plans to identify and commercialize innovative companies and create synergies between those companies and the research community. 

“This strategic acquisition will allow us to fully realize the potential of a combined Ehave and PsyTech. We believe this combination will create more value for scientists, innovators, regulators, investors, our current and potential business partners, and advocates from around the world. We aim to open minds to the potential of psychedelic medicine,” said Ehave CEO Ben Kaplan. “First and foremost, with this acquisition, we plan to make the information from our PsyTech Conferences more accessible to investors and industry professionals.”

“PsyTech looks forward to what it can do for the psychedelics community and what it can do to develop solid ventures in psychedelic therapeutics as part of Ehave.” said PsyTech Managing Director Hayim Raclaw. “Our ventures through PsyTech Discovery and ethos remain the same, and this move should enable us to pursue that mission with more resources and have greater positive impact.”

“This deal will ensure that PsyTech becomes all that it can become, building a psychedelics ecosystem to accelerate innovation and bring value to patients, consumers, researchers, investors, and policymakers.” Said Saul Kaye, CEO of ICAN: Israel-Cannabis, PsyTech’s largest shareholder and home of the incubator that birthed PsyTech. 

In other news, Ehave, Inc. and its subsidiary PsyTech hosted the latest in the series of PsyTech Webinars at 1:00 PM ET on Wednesday, May 6, 2020. This investor-focused edition of the webinar series was open to all and attracted individual and institutional investors, advisors, and analysts. 

The featured industry experts included:

Bruce Linton, Former CEO of Canopy Growth and activist investor in psychedelics

Jayashree Mitra, Partner, Zuber Lawler & Del Duca

Alex Speiser, COO, Orthogonal Thinker

Hayim Raclaw (Moderator) Managing Director, PsyTech

To find out about upcoming PsyTech Events, please visit https://www.psytech.biz/psytech-vitual-summit/ or email our Investor Relations representative, Gabe Rodriguez at ir@ehave.com

The last PsyTech Webinar on April 22, 2020 was a huge success, and featured Christian Angermayer, the Founder of ATAI Life Sciences, Rick Doblin founder of MAPS, and Dr. Rosalind Watts of Imperial College Center for Psychedelic Research.  Participants received information from industry experts on the latest advancements in psychedelic medicine, research, and policy.  We also raised over $10,000 for the important work being done by MAPS, thanks in large part to Mr. Angermeyer.

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

About PsyTech

PsyTech is building a vibrant community designed to explore psychedelic health and wellness, combat stigma, and accelerate innovation. PsyTech operates two matrix divisions that deliver revenue and build an equity portfolio: PsyTech Connect and PsyTech Discovery. PsyTech Connect is a premier psychedelic community platform for live and virtual conferences and an online portal for psychedelics content.  PsyTech Discovery will develop ventures in psychedelic therapeutics and education. Learn more about PsyTech at www.psytech.biz 

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investor Relations, please contact:

Gabe Rodriguez Phone: (623) 261-9046 Email: ir@ehave.com

Close Menu

PSYTECH VIRTUAL SUMMIT

MAY 25 & 26

2 Days of Learning, Community Building and Discussions to drive innovation and acceptance of mainstreaming psychedelics with: